Idiopathic juxtafoveolar retinal telangiectasia: a review and case report

Tasca, Jennifer; Grogg, Jane Ann

doi:10.1016/s0953-4431(99)00048-x

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IJRT may occur as a primary disorder, either congenital or acquired, or may be involved in other systemic or ocular diseases. Dilation and incompetence of juxtafoveolar capillaries lead to the development of intraretinal edema and/or choroidal neovascularization (CNV) [1]. Idiopathic juxtafoveolar telangiectasia is a condition of unknown etiology, characterized by abnormal retinal vessels usually located temporally to the fovea.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal Ranibizumab and Laser Photocoagulation in the Management of Idiopathic Juxtafoveolar Retinal Telangiectasia Type 1: A Case Report

Ciarnella¹,

Verrilli²,

Fenicia³

et al. 2012

Case Rep Ophthalmol

View full text Add to dashboard Cite

Background: Idiopathic juxtafoveolar retinal telangiectasia (IJRT) type 1 represents an uncommon cause of congenital unilateral visual loss and it typically affects males. Decrease in visual acuity is caused by serous and lipid exudation into the fovea with cystoid macular edema. In some cases, spontaneous resolution may be observed, but when there is a progressive loss of visual acuity, laser photocoagulation is often necessary. This treatment is not always successful and therapy for this condition is still controversial. Case Presentation: A 57-year-old man referred a 2-month history of blurred and distorted vision in the right eye. Best-corrected visual acuity was 20/50 in the right eye and 20/20 in the left eye. Fundus examination showed temporal macular edema, confirmed by optical coherence tomography. Fluorescein angiography showed a localized area of hyperfluorescence probably due to telangiectasia type 1 located below the inferior temporal area of the fovea. A combined therapy of intravitreal ranibizumab injection and laser photocoagulation was performed. Visual acuity improved from 20/50 to 20/32 and the therapy was well tolerated by the patient. After 3 years of follow-up, both visual acuity and fundus examination were stable. Conclusions: This case suggests that the combined use of ranibizumab and laser photocoagulation may be considered an effective treatment for JRT type 1, leading to an improvement in both visual acuity and macular edema. We believe that intravitreal ranibizumab injection associated with laser photocoagulation should be considered as treatment for IJRT type 1.

show abstract

Section: Introductionmentioning

confidence: 99%